Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics

Variable	Tübingen	Sydney
No. of patients	6	10
Sex, (female)	3 (50%)	7 (70%)
Age, y	36 (20-62)	65 (34-74)
PLT count (at admission)∗	42 (14-60)	48 (18-124)
D-dimer	31 (12.4-73)	40† (19.8-132)
Mean OD EIA	2.91 (2.07-3.48)	2.46 (1.90-2.95)
Positive PF4-modified HIPA (Tübingen)/SRA (Sydney)	6 (100%)	10 (100%)
Vaccine
AstraZeneca	5 (83%)	10 (100%)
Johnson & Johnson	1 (17%)	0
Days after vaccination	9 (7-28)	10 (4-25)
Thrombosis	6 (100%)	10 (100%)
Cerebral venous sinus thrombosis	4 (67%)	2 (20%)
Splanchnic thrombosis	0	3 (30%)
Deep vein thrombosis	0	6 (60%)
Pulmonary embolism	1 (17%)	1 (10%)
Internal jugular vein thrombosis	0	1 (10%)
Arterial thrombosis	2 (33%)	0

Variable	Tübingen	Sydney
No. of patients	6	10
Sex, (female)	3 (50%)	7 (70%)
Age, y	36 (20-62)	65 (34-74)
PLT count (at admission)∗	42 (14-60)	48 (18-124)
D-dimer	31 (12.4-73)	40† (19.8-132)
Mean OD EIA	2.91 (2.07-3.48)	2.46 (1.90-2.95)
Positive PF4-modified HIPA (Tübingen)/SRA (Sydney)	6 (100%)	10 (100%)
Vaccine
AstraZeneca	5 (83%)	10 (100%)
Johnson & Johnson	1 (17%)	0
Days after vaccination	9 (7-28)	10 (4-25)
Thrombosis	6 (100%)	10 (100%)
Cerebral venous sinus thrombosis	4 (67%)	2 (20%)
Splanchnic thrombosis	0	3 (30%)
Deep vein thrombosis	0	6 (60%)
Pulmonary embolism	1 (17%)	1 (10%)
Internal jugular vein thrombosis	0	1 (10%)
Arterial thrombosis	2 (33%)	0

Continuous variables are expressed as median (range).

EIA, enzyme immune-assay; HIPA, heparin-induced platelet activation assay; OD, optical density; SRA, serotonin-release assay.

Reference range PLT count (150 × 10⁹ to 450 × 10⁹/L).

Upper limit of normal.